Galectin Role in Periodontal Disease

This study aimed at exploring the effect of nonsurgical periodontal treatment on galectin 1 and 3 GCF levels in patients having gingivitis, periodontitis stage III compared to periodontally healthy individuals and if galectin-1 and -3 could serve as diagnostic markers and/or therapeutic targets for periodontitis, in addition to revealing their possible role in the periodontal disease.

45 systemically healthy participants were enrolled in this investigation, equally subdivided into three groups of 15 patients each: gingivitis, periodontitis (stage III) and control group with healthy gingiva. Probing depth, clinical attachment level, gingival and plaque index were registered. GCF levels of galectin-1 and -3 were evaluated in all included groups (before and after non-surgical treatment for periodontitis group) using enzyme linked immune-sorbent assay (ELISA) kit.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Gingivitis Gingival Diseases Infections Mouth Diseases Periodontal Diseases Periodontitis Stomatognathic Diseases

Age range

25 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

faculty of dentistry, Fayoum university

Al Fayyum, Egypt

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Non-smokers from both genders.
Not suffering from systemic diseases, pregnancy/lactation.
Not taking contraceptive pills, antibiotics, anti-inflammatory, or immunosuppressive drugs before inclusion in the study by 6 months.
Patients with only gingivitis or periodontitis stage III.
Periodontitis patients who did not receive any professional periodontal treatment in the last 6 months.

Exclusion criteria

smokers.
having systemic diseases, pregnancy/lactation.
taking contraceptive pills, antibiotics, anti-inflammatory, or immunosuppressive drugs in the past 6 months.
Patients having periodontitis any other stage than stage III.
Periodontitis patients who receive any professional periodontal treatment in the last 6 months.

Treatment and study plan

GCF sample collection

Diagnostic Test

collecting GCF from deepest sites by paper points

Non-surgical periodontal treatment

Procedure

performing scaling and root planning using ultrasonic device and manual curettes

Primary outcomes

assessment of gal-1 and gal-3 in GCF samples

Time frame: an average of about 10 months to assess level of gal-1 & -3 after collection of GCF samples at baseline (1st appointment) for all groups and another sample collection after 4 weeks for group II after performing scaling and root planning

samples are to be sent to biochemistry lab to measure galectin levels

Sponsors and collaborators

Lead sponsor

Fayoum University

Other

Registry information

Official study title

Outcome of Non-surgical Periodontal Treatment on Gal-1 & Gal-3 GCF Levels in Periodontitis Patients

Important dates

Study start: 2023
Primary completion: 2023
Study completion: 2023
First posted: Sep 15, 2023
Registry last updated: Jan 12, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed